Pharmaceutical Preparations · NYSE
For the period ended December 31, 2023, PFIZER INC reported $59.6 billion across 3 reportable segments: Biopharma ($57.19B, 96.0%), Business Innovation ($1.31B, 2.2%), Other / unallocated ($1.06B, 1.8%). Biopharma's share of the total is up from 92.9% for the period ended December 31, 2019.
For the period ended December 31, 2025, PFIZER INC reported $62.6 billion across 3 geographies: U.S. ($37.08B, 59.2%), International Developed Markets ($16.19B, 25.9%), International Emerging Markets ($9.31B, 14.9%). U.S.'s share of the total is up from 49.7% for the period ended December 31, 2019.
PFIZER INC annual revenue by reportable segment, as disclosed in SEC filings.
| Segment | FY2019 | FY2020 | FY2022 | FY2023 | Share |
|---|---|---|---|---|---|
| Biopharma | $38.01B | $40.72B | $98.99B | $57.19B | 96.0% |
| Business Innovation | — | — | $1.34B | $1.31B | 2.2% |
| Other / unallocated | $2.08B | — | $845.0M | $1.06B | 1.8% |
| Pfizer CentreOne | $810.0M | $926.0M | — | — | — |
| Total | $40.91B | $41.65B | $101.17B | $59.55B |
PFIZER INC annual revenue by geography, as disclosed in SEC filings.
| Region | FY2020 | FY2022 | FY2023 | FY2024 | FY2025 | Share |
|---|---|---|---|---|---|---|
| U.S. | $21.45B | $43.32B | $28.14B | $38.69B | $37.08B | 59.2% |
| International Developed Markets | — | $40.53B | $20.91B | $16.06B | $16.19B | 25.9% |
| International Emerging Markets | — | $17.32B | $10.50B | $8.88B | $9.31B | 14.9% |
| Emerging Markets | $8.37B | — | — | — | — | — |
| Developed Europe | $7.79B | — | — | — | — | — |
| Developed Rest Of World | $4.04B | — | — | — | — | — |
| Total | $41.65B | $101.17B | $59.55B | $63.63B | $62.58B |
Extracted from the XBRL segment tags in the company’s SEC filings. Figures are as reported and are not restated or adjusted.
Data: SEC EDGAR (financials, KPIs, segments) · Yahoo Finance (price, splits, metrics, analyst estimates, news headlines). Not financial advice.